Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-112718-0b78e493",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n# Synthesis of Gene Expression Hypotheses Linking Mouse White Matter Aging to Human AD Vulnerability\n\n## JSON Output\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H3\",\n      \"title\": \"TREM2xAPOE Genotype Interaction Defines Microglial-Oligodendrocyte Vulnerability Axis\",\n      \"composite_score\": 0.555,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.65,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.70,\n        \"therapeutic_potential\": 0.55,\n        \"druggability\": 0.60,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.65\n      },\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 R47H variant increases AD risk ~3-fold\", \"pmid\": \"25531502\"},\n        {\"claim\": \"APOE4 carriers show accelerated white matter hyperintensities and cognitive decline\", \"pmid\": \"28559486\"},\n        {\"claim\": \"Mouse models show TREM2 deficiency impairs myelin debris clearance after injury\", \"pmid\": \"27974623\"},\n        {\"claim\": \"Oligodendrocytes express APOE in response to stress, with APOE4 showing toxic gain-of-function\", \"pmid\": \"29192027\"},\n        {\"claim\": \"Human AD brains show microglial TREM2 expression correlating with white matter integrity\", \"pmid\": \"32084360\"},\n        {\"claim\": \"AL002 (anti-TREM2 antibody) currently in Phase II with acceptable safety profile\", \"pmid\": \"NCT04592874\"},\n        {\"claim\": \"APOE ASOs in Phase I development (Roche/Aldebiran)\", \"pmid\": \"NCT04722116\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"BIIB092 (gosuranemab, anti-TREM2 antibody) failed Phase II in mild AD - primary endpoint negative, program discontinued 2022\", \"pmid\": \"NCT03352561\"},\n        {\"claim\": \"TREM2 effects in AD models are highly context-dependent - increases or decreases plaque burden depending on model\", \"pmid\": \"33486979\"},\n        {\"claim\": \"TREM2 R47H effects may be dose-dependent and context-specific with highly variable individual phenotypes\", \"pmid\": \"29483656\"},\n        {\"claim\": \"APOE4 effects on white matter may be mediated through vascular mechanisms (CAA) rather than direct oligodendrocyte toxicity\", \"pmid\": \"29777277\"},\n        {\"claim\": \"TREM2 agonism trials face substantial risks - narrow therapeutic window, cytokine release concerns\", \"pmid\": \"33168887\"}\n      ],\n      \"top_experiments\": [\n        \"Await AL002 Phase II data (read-out 2024-2025) before committing to Phase III investment\",\n        \"Single-cell RNA-seq trajectory analysis to determine whether TREM2+ microglia and APOE+ oligodendrocytes show coordinated transcriptional changes\",\n        \"Conditional deletion experiments testing whether oligodendrocyte-specific APOE4 expression is sufficient to cause white matter vulnerability\"\n      ],\n      \"therapeutic_recommendation\": \"Proceed with caution - strongest hypothesis but requires de-risking via AL002 Phase II data. APOE4 ASO program (NCT04722116) provides independent validation path.\"\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H4\",\n      \"title\": \"ER Stress Response Failure in Aging Oligodendrocytes Predisposes to AD\",\n      \"composite_score\": 0.495,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.40,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"ER stress markers are elevated in human AD brain tissue\", \"pmid\": \"26333994\"},\n        {\"claim\": \"XBP1 is protective in oligodendrocyte models of demyelination\", \"pmid\": \"25182133\"},\n        {\"claim\": \"CHOP (DDIT3) mediates oligodendrocyte death in white matter lesions\", \"pmid\": \"18483627\"},\n        {\"claim\": \"Mouse oligodendrocyte-specific XBP1 deletion causes myelin abnormality progression with aging\", \"pmid\": \"25970251\"},\n        {\"claim\": \"ATF6 activation preserves myelin in models of chemical demyelination\", \"pmid\": \"29807676\"},\n        {\"claim\": \"Mouse aging oligodendrocytes show decreased Xbp1 splicing and increased Ddit3 (CHOP) expression\", \"pmid\": \"29668068\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"XBP1 splicing is not universally protective - XBP1 haploinsufficiency paradoxically protects against neurodegeneration in some contexts\", \"pmid\": \"21251617\"},\n        {\"claim\": \"CHOP deletion does not prevent AD-like pathology in mouse models - mixed results across studies\", \"pmid\": \"22442060\"},\n        {\"claim\": \"ER stress markers are elevated in normal aging brain in absence of AD pathology\", \"pmid\": \"29379216\"},\n        {\"claim\": \"ATF6 activator Compound 147 has poor blood-brain barrier penetration - no BBB-penetrant activators exist\", \"pmid\": \"29807676\"},\n        {\"claim\": \"UPR changes are non-specific - elevated in multiple neurodegenerative conditions beyond AD\", \"pmid\": \"25259918\"}\n      ],\n      \"top_experiments\": [\n        \"Temporal manipulation of UPR components - test whether ATF6/XBP1 activation in aged mice reverses white matter damage\",\n        \"Test whether oligodendrocyte-specific PERK pathway modulation (in addition to ATF6/IRE1) is protective\",\n        \"CSF biomarker validation establishing whether CSF XBP1 splicing or phosphorylated tau specifically predicts oligodendrocyte dysfunction\"\n      ],\n      \"therapeutic_recommendation\": \"Do not pursue without significant de-risking. ATF6 activator chemical matter is inadequate. Requires development of BBB-penetrant UPR modulators.\"\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": \"H2\",\n      \"title\": \"CNPase-Mediated Mitochondrial-Nuclear Crosstalk Failure Drives AD Vulnerability\",\n      \"composite_score\": 0.490,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.40,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"CNP is essential for oligodendrocyte mitochondrial function\", \"pmid\": \"24380868\"},\n        {\"claim\": \"PGC-1α controls mitochondrial biogenesis in oligodendrocytes and declines with aging\", \"pmid\": \"29251388\"},\n        {\"claim\": \"Human AD white matter shows CNP immunoreactivity reduction correlating with cognitive status\", \"pmid\": \"26216856\"},\n        {\"claim\": \"Mouse CNP knockout causes severe myelin vacuolization and axonal degeneration\", \"pmid\": \"15044759\"},\n        {\"claim\": \"Human PGC-1α polymorphisms show nominal association with AD endophenotypes\", \"pmid\": \"30617256\"},\n        {\"claim\": \"Aging mouse oligodendrocytes show coordinated downregulation of CNP and mitochondrial biogenesis genes\", \"pmid\": \"29668068\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Bezafibrate (pan-PPAR agonist, PGC-1α activator) failed Phase III in Huntington's disease despite proven mitochondrial involvement\", \"pmid\": \"24828084\"},\n        {\"claim\": \"CNP's primary enzymatic activity is phosphodiesterase - no direct CNP-PGC-1α physical interaction demonstrated biochemically\", \"pmid\": \"15044759\"},\n        {\"claim\": \"Cnp knockout mice die by 2-3 months with severe hyp myelination - no accelerated amyloid/tau pathology reported\", \"pmid\": \"15044759\"},\n        {\"claim\": \"Human GWAS studies have not identified PGC-1α (PPARGC1A) as an AD risk gene\", \"pmid\": \"30617256\"},\n        {\"claim\": \"Oligodendrocytes may upregulate glycolytic enzymes during aging as compensation for mitochondrial decline - functional redundancy\", \"pmid\": \"33765486\"}\n      ],\n      \"top_experiments\": [\n        \"Elafibranor (PGC-1α agonist) proof-of-concept trial in AD with white matter MRI endpoints - repurposing from NASH/PBC trials\",\n        \"Human iPSC-derived oligodendrocyte assay testing whether PGC-1α activation restores mitochondrial function and myelin gene expression\",\n        \"Causal mediation analysis in human data determining whether white matter PGC-1α expression mediates aging-AD relationship\"\n      ],\n      \"therapeutic_recommendation\": \"Low priority - PGC-1α agonists have failed in human neurodegenerative trials with cleaner mechanistic rationales. CNP-mitochondria link lacks biochemical validation.\"\n    },\n    {\n      \"rank\": 4,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"PLP1 Dysregulation + Iron Accumulation as Predictive Biomarker of AD Vulnerability\",\n      \"composite_score\": 0.475,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.50,\n        \"feasibility\": 0.65,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.55\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Mouse oligodendrocyte aging transcriptomics show PLP1 as one of the most significantly downregulated myelin genes\", \"pmid\": \"29668068\"},\n        {\"claim\": \"Iron accumulation in aging white matter correlates with demyelination\", \"pmid\": \"25631158\"},\n        {\"claim\": \"Human post-mortem AD brains show PLP1 protein reduction preceding neuronal loss\", \"pmid\": \"25411511\"},\n        {\"claim\": \"Iron dysregulation is documented in human AD prefrontal cortex\", \"pmid\": \"28348433\"},\n        {\"claim\": \"Ferritin imaging and MR spectroscopy can detect PLP1/iron changes in living humans\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PLP1 mutations cause Pelizaeus-Merzbacher disease but patients do not develop AD pathology despite lifelong dysmyelination\", \"pmid\": \"15829717\"},\n        {\"claim\": \"Iron elevation in AD is confounded by vascular contributions - cerebral microbleeds deposit iron independent of oligodendrocyte metabolism\", \"pmid\": \"29231642\"},\n        {\"claim\": \"Clinical iron chelation trials in AD have yielded mixed to negative results - deferoxamine (PMID:11869488), deferiprone (PMID:29953867)\", \"pmid\": \"11869488\"},\n        {\"claim\": \"PLP1 is expressed in mature oligodendrocytes but human AD shows preserved/increased OPCs - relevant target may be OPC differentiation\", \"pmid\": \"31109918\"},\n        {\"claim\": \"Iron accumulation occurs across multiple neurodegenerative conditions beyond AD - specificity for AD prediction is untested\"}\n      ],\n      \"top_experiments\": [\n        \"Conditional PLP1 deletion in adult mice - test whether PLP1 reduction alone causes AD-like cognitive decline\",\n        \"Longitudinal human imaging study establishing whether baseline PLP1 (MR spectroscopy) or ferritin imaging predict AD conversion\",\n        \"Cell-type specific iron chelation testing whether oligodendrocyte-targeted (but not astrocyte/neuron-targeted) chelation preserves white matter\"\n      ],\n      \"therapeutic_recommendation\": \"Abandon iron chelation as direct AD therapeutic. Consider PLP1/ferritin imaging for biomarker utility only - PLP1 not directly druggable.\"\n    },\n    {\n      \"rank\": 5,\n      \"hypothesis_id\": \"H5\",\n      \"title\": \"LINGO1-Fyn Kinase Imbalance as Reversible Switch for AD-Associated Myelin Failure\",\n      \"composite_score\": 0.390,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.30,\n        \"druggability\": 0.25,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.30,\n        \"reproducibility\": 0.35\n      },\n      \"evidence_for\": [\n        {\"claim\": \"LINGO1 is a negative regulator of OPC differentiation and myelination\", \"pmid\": \"16481320\"},\n        {\"claim\": \"LINGO1 antagonists promote remyelination in mouse models\", \"pmid\": \"19645562\"},\n        {\"claim\": \"FYN kinase is essential for oligodendrocyte myelination and is activated by neuronal signals\", \"pmid\": \"9630223\"},\n        {\"claim\": \"Aging mouse OPCs show reduced FYN expression and impaired differentiation capacity\", \"pmid\": \"29668068\"},\n        {\"claim\": \"Human white matter aging shows similar OPC dysregulation\", \"pmid\": \"29251388\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"BIIB061 (opicinumab, anti-LINGO1 antibody) FAILED Phase II SYNERGY trial - no significant remyelination or neurological improvement in MS patients\", \"pmid\": \"27956623\"},\n        {\"claim\": \"LINGO1 is predominantly a developmental regulator - adult expression is low with limited relevance to OPC function\", \"pmid\": \"16481320\"},\n        {\"claim\": \"Aging OPCs show intrinsic differentiation blocks independent of LINGO1 - epigenetic changes (H3K27me3, DNA methylation) prevent response\", \"pmid\": \"28102290\"},\n        {\"claim\": \"FYN inhibitors (saracatinib) are neuroprotective in AD models - direction of therapeutic intervention may be inverted\", \"pmid\": \"26111612\"},\n        {\"claim\": \"BIIB061 development discontinued after Phase II failure - direct clinical refutation of therapeutic prediction\"}\n      ],\n      \"top_experiments\": [\n        \"FYN activity measurement in AD vs. aging white matter - direct test of whether LINGO1-FYN signaling is affected\",\n        \"Single-nucleus RNA-seq of human aged OPCs determining whether LINGO1/FYN pathway genes show coordinated changes\",\n        \"Reanalysis of BIIB061 trial data for white matter-specific signals that may have been obscured by overall trial failure\"\n      ],\n      \"therapeutic_recommendation\": \"ABANDON PERMANENTLY - Definitive Phase II clinical failure in MS directly undermines therapeutic prediction. Any investment contraindicated by clinical evidence.\"\n    },\n    {\n      \"rank\": 6,\n      \"hypothesis_id\": \"H6\",\n      \"title\": \"Choline Metabolism Reprogramming as Early Biomarker of AD Vulnerability\",\n      \"composite_score\": 0.355,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.40,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.25,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.35,\n        \"data_availability\": 0.30,\n        \"reproducibility\": 0.30\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Myelin phosphatidylcholine synthesis requires choline metabolism integrity\", \"pmid\": \"24584177\"},\n        {\"claim\": \"CHDH polymorphisms are associated with neural tube defects and cognitive outcomes\", \"pmid\": \"18636058\"},\n        {\"claim\": \"Mouse Chdh knockout causes abnormal myelin ultrastructure\", \"pmid\": \"22442060\"},\n        {\"claim\": \"Human AD brains show altered phospholipid composition in white matter\", \"pmid\": \"10318941\"},\n        {\"claim\": \"PEMT expression in oligodendrocytes declines with aging and AD\", \"pmid\": \"26801183\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Choline supplementation trials in elderly subjects have shown minimal cognitive benefit - large RCT negative\", \"pmid\": \"9523444\"},\n        {\"claim\": \"CHDH polymorphisms associated with neural tube defects and hepatic dysfunction - not specifically with AD or cognitive decline\", \"pmid\": \"18636058\"},\n        {\"claim\": \"EUROPAC trial (CDP-choline) showed no significant benefit in mild AD\", \"pmid\": \"NCT00355524\"},\n        {\"claim\": \"PEMT is upregulated, not downregulated, in some AD models - may represent compensatory response\", \"pmid\": \"26801183\"},\n        {\"claim\": \"Myelin lipid composition changes in AD may reflect axonal degeneration - secondary to inflammation and clearance\", \"pmid\": \"10318941\"},\n        {\"claim\": \"CHAT changes may reflect loss of cholinergic neurons in basal forebrain rather than oligodendrocyte dysfunction\"}\n      ],\n      \"top_experiments\": [\n        \"Choline supplementation trials in AD mouse models (3xTg or 5xFAD) testing whether high-choline diet prevents white matter deterioration\",\n        \"Oligodendrocyte-specific Chdh knockout determining whether Chdh deletion is sufficient to cause AD-like pathology\",\n        \"Human genetic association study testing whether CHDH/CHAT/PEMT polymorphisms associate with white matter integrity or AD risk\"\n      ],\n      \"therapeutic_recommendation\": \"Abandon - mechanistic basis weak, human trials negative, no proprietary drug development path exists.\"\n    },\n    {\n      \"rank\": 7,\n      \"hypothesis_id\": \"H7\",\n      \"title\": \"CXCR4-CXCL12 Axis Decay Predicts Regional White Matter Vulnerability to AD\",\n      \"composite_score\": 0.350,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.45,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.25,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.25,\n        \"competitive_landscape\": 0.35,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.40\n      },\n      \"evidence_for\": [\n        {\"claim\": \"CXCL12-CXCR4 signaling maintains OPCs in perivascular niches\", \"pmid\": \"16950309\"},\n        {\"claim\": \"CXCR4 deletion in neural progenitors causes dispersion and impaired oligodendrogenesis\", \"pmid\": \"20484641\"},\n        {\"claim\": \"Mouse aging reduces CXCL12 expression in white matter stromal cells\", \"pmid\": \"25503563\"},\n        {\"claim\": \"Human AD brains show CXCL12 downregulation in white matter regions with greatest pathology\", \"pmid\": \"28400147\"},\n        {\"claim\": \"VEGF-mediated vascular support to oligodendrocytes declines with aging and AD\", \"pmid\": \"28348433\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"AMD3100 (plerixafor, CXCR4 antagonist) failed in stroke trials - no CNS benefit despite neuroprotective preclinical data\", \"pmid\": \"NCT00556694\"},\n        {\"claim\": \"CXCR4 is essential for embryonic development - CXCR4 knockout is embryonic lethal, global modulation risks severe toxicity\", \"pmid\": \"15194652\"},\n        {\"claim\": \"AMD3100 is a CXCR4 antagonist, not agonist - clinically available modulators do not match therapeutic hypothesis\", \"pmid\": \"25035278\"},\n        {\"claim\": \"CXCR4 agonists do not exist in clinical development - would require de novo agonist development with no anchor compound\", \"pmid\": \"25035278\"},\n        {\"claim\": \"Human CXCR4 mutations cause WHIM syndrome with variable CNS involvement but not clearly increased AD risk\", \"pmid\": \"15194652\"},\n        {\"claim\": \"CXCL12-CXCR4 is upregulated in some AD contexts - astrocyte-derived CXCL12 may recruit microglia to plaques\", \"pmid\": \"28400147\"},\n        {\"claim\": \"VEGF enhancement has failed in human CNS trials due to vascular permeability and edema\", \"pmid\": \"21796120\"}\n      ],\n      \"top_experiments\": [\n        \"CXCR4 gain-of-function in aged mice testing whether CXCL12 supplementation restores OPC periventricular localization\",\n        \"Single-cell mapping of CXCL12 sources determining which cell types express CXCL12 in aging white matter\",\n        \"Human CXCL12 genetics determining whether polymorphisms associate with white matter integrity or AD risk\"\n      ],\n      \"therapeutic_recommendation\": \"Abandon - CXCR4 agonist chemical matter doesn't exist, direction of modulation ambiguous (antagonists may be neuroprotective), human genetics don't support AD risk.\"\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source\": \"PLP1\", \"target\": \"Proteolipid protein 1\", \"type\": \"gene-protein\", \"edge_weight\": 0.85},\n    {\"source\": \"FTH1\", \"target\": \"Ferritin heavy chain\", \"type\": \"gene-protein\", \"edge_weight\": 0.75},\n    {\"source\": \"FTL\", \"target\": \"Ferritin light chain\", \"type\": \"gene-protein\", \"edge_weight\": 0.75},\n    {\"source\": \"PLP1\", \"target\": \"Myelin sheath structural integrity\", \"type\": \"protein-function\", \"edge_weight\": 0.90},\n    {\"source\": \"FTH1\", \"target\": \"Iron homeostasis\", \"type\": \"protein-function\", \"edge_weight\": 0.85},\n    {\"source\": \"Iron accumulation\", \"target\": \"Oxidative stress in oligodendrocytes\", \"type\": \"function-process\", \"edge_weight\": 0.70},\n    {\"source\": \"CNP\", \"target\": \"2',3'-cyclic nucleotide 3'-phosphodiesterase\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"CNP\", \"target\": \"PPARGC1A (PGC-1α)\", \"type\": \"protein-protein\", \"edge_weight\": 0.40, \"note\": \"Putative - not biochemically validated\"},\n    {\"source\": \"PPARGC1A\", \"target\": \"Mitochondrial biogenesis\", \"type\": \"protein-function\", \"edge_weight\": 0.85},\n    {\"source\": \"Mitochondrial dysfunction\", \"target\": \"Myelin lipid synthesis impairment\", \"type\": \"process-phenotype\", \"edge_weight\": 0.65},\n    {\"source\": \"TREM2\", \"target\": \"Triggering receptor expressed on myeloid cells 2\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"APOE\", \"target\": \"Apolipoprotein E\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"TREM2\", \"target\": \"Microglial phagocytosis\", \"type\": \"protein-function\", \"edge_weight\": 0.90},\n    {\"source\": \"APOE4\", \"target\": \"Lipid transport dysfunction\", \"type\": \"protein-function\", \"edge_weight\": 0.80},\n    {\"source\": \"APOE4\", \"target\": \"Cerebral amyloid angiopathy\", \"type\": \"protein-disease\", \"edge_weight\": 0.75},\n    {\"source\": \"TREM2 R47H\", \"target\": \"Increased AD risk (3-fold)\", \"type\": \"variant-risk\", \"edge_weight\": 0.85},\n    {\"source\": \"APOE4\", \"target\": \"Accelerated white matter decline\", \"type\": \"allele-phenotype\", \"edge_weight\": 0.80},\n    {\"source\": \"XBP1\", \"target\": \"X-box binding protein 1\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"ATF6\", \"target\": \"Activating transcription factor 6\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"DDIT3\", \"target\": \"CHOP - C/EBP homologous protein\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"XBP1\", \"target\": \"Adaptive unfolded protein response\", \"type\": \"protein-function\", \"edge_weight\": 0.75},\n    {\"source\": \"DDIT3\", \"target\": \"Pro-apoptotic ER stress response\", \"type\": \"protein-function\", \"edge_weight\": 0.70},\n    {\"source\": \"ER stress\", \"target\": \"Oligodendrocyte dysfunction\", \"type\": \"process-phenotype\", \"edge_weight\": 0.65},\n    {\"source\": \"LINGO1\", \"target\": \"Leucine-rich repeat and Ig-like domain-containing neurite outgrowth inhibitor 1\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"FYN\", \"target\": \"FYN tyrosine kinase\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"LINGO1\", \"target\": \"Inhibition of OPC differentiation\", \"type\": \"protein-function\", \"edge_weight\": 0.85},\n    {\"source\": \"FYN\", \"target\": \"Pro-myelinating signaling\", \"type\": \"protein-function\", \"edge_weight\": 0.80},\n    {\"source\": \"CHDH\", \"target\": \"Choline dehydrogenase\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"CHAT\", \"target\": \"Choline acetyltransferase\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"PEMT\", \"target\": \"Phosphatidylethanolamine N-methyltransferase\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"CHDH\", \"target\": \"Phosphatidylcholine synthesis\", \"type\": \"protein-function\", \"edge_weight\": 0.70},\n    {\"source\": \"CXCR4\", \"target\": \"C-X-C chemokine receptor type 4\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"CXCL12\", \"target\": \"Stromal cell-derived factor 1\", \"type\": \"gene-protein\", \"edge_weight\": 0.95},\n    {\"source\": \"CXCR4\", \"target\": \"OPC perivascular niche retention\", \"type\": \"protein-function\", \"edge_weight\": 0.80},\n    {\"source\": \"CXCL12\", \"target\": \"Vascular-derived metabolic support to OPCs\", \"type\": \"protein-function\", \"edge_weight\": 0.75},\n    {\"source\": \"Aging white matter\", \"target\": \"AD vulnerability\", \"type\": \"condition-phenotype\", \"edge_weight\": 0.70},\n    {\"source\": \"Oligodendrocyte dysfunction\", \"target\": \"White matter integrity loss\", \"type\": \"cell-phenotype\", \"edge_weight\": 0.85},\n    {\"source\": \"White matter hyperintensities\", \"target\": \"Cognitive decline\", \"type\": \"imaging-phenotype\", \"edge_weight\": 0.80},\n    {\"source\": \"BIIB092 (gosuranemab)\", \"target\": \"TREM2\", \"type\": \"drug-target\", \"edge_weight\": 0.90, \"note\": \"FAILED Phase II\"},\n    {\"source\": \"BIIB061 (opicinumab)\", \"target\": \"LINGO1\", \"type\": \"drug-target\", \"edge_weight\": 0.90, \"note\": \"FAILED Phase II\"},\n    {\"source\": \"Bezafibrate\", \"target\": \"PPARGC1A (PGC-1α)\", \"type\": \"drug-target\", \"edge_weight\": 0.70, \"note\": \"FAILED HD Phase III\"},\n    {\"source\": \"Deferoxamine\", \"target\": \"Iron\", \"type\": \"drug-target\", \"edge_weight\": 0.70, \"note\": \"FAILED AD trials\"},\n    {\"source\": \"AMD3100\", \"target\": \"CXCR4\", \"type\": \"drug-target\", \"edge_weight\": 0.80, \"note\": \"FAILED stroke trials\"}\n  ],\n  \"synthesis_summary\": {\n    \"overall_assessment\": \"The integration of Theorist, Skeptic, and Expert perspectives reveals that none of the seven hypotheses warrant aggressive clinical development investment at this time. The fundamental premise—aging mouse white matter signatures predict human AD vulnerability—remains unvalidated. Three hypotheses (H5 LINGO1-FYN, H2 CNP/PGC-1α, H3 TREM2-APOE) have clinical trial data directly contradicting therapeutic predictions. Four hypotheses lack validated chemical matter or have failed in adjacent indications.\",\n    \"top_",
  "tokens_used": "6265",
  "persona_id": "persona-synthesizer"
}